Cargando…
Methodology for clinical genotyping of CYP2D6 and CYP2C19
Many antidepressants, atomoxetine, and several antipsychotics are metabolized by the cytochrome P450 enzymes CYP2D6 and CYP2C19, and guidelines for prescribers based on genetic variants exist. Although some laboratories offer such testing, there is no consensus regarding validated methodology for cl...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608805/ https://www.ncbi.nlm.nih.gov/pubmed/34811360 http://dx.doi.org/10.1038/s41398-021-01717-9 |
_version_ | 1784602807983144960 |
---|---|
author | Carvalho Henriques, Beatriz Buchner, Avery Hu, Xiuying Wang, Yabing Yavorskyy, Vasyl Wallace, Keanna Dong, Rachael Martens, Kristina Carr, Michael S. Behroozi Asl, Bahareh Hague, Joshua Sivapalan, Sudhakar Maier, Wolfgang Dernovsek, Mojca Z. Henigsberg, Neven Hauser, Joanna Souery, Daniel Cattaneo, Annamaria Mors, Ole Rietschel, Marcella Pfeffer, Gerald Hume, Stacey Aitchison, Katherine J. |
author_facet | Carvalho Henriques, Beatriz Buchner, Avery Hu, Xiuying Wang, Yabing Yavorskyy, Vasyl Wallace, Keanna Dong, Rachael Martens, Kristina Carr, Michael S. Behroozi Asl, Bahareh Hague, Joshua Sivapalan, Sudhakar Maier, Wolfgang Dernovsek, Mojca Z. Henigsberg, Neven Hauser, Joanna Souery, Daniel Cattaneo, Annamaria Mors, Ole Rietschel, Marcella Pfeffer, Gerald Hume, Stacey Aitchison, Katherine J. |
author_sort | Carvalho Henriques, Beatriz |
collection | PubMed |
description | Many antidepressants, atomoxetine, and several antipsychotics are metabolized by the cytochrome P450 enzymes CYP2D6 and CYP2C19, and guidelines for prescribers based on genetic variants exist. Although some laboratories offer such testing, there is no consensus regarding validated methodology for clinical genotyping of CYP2D6 and CYP2C19. The aim of this paper was to cross-validate multiple technologies for genotyping CYP2D6 and CYP2C19 against each other, and to contribute to feasibility for clinical implementation by providing an enhanced range of assay options, customizable automated translation of data into haplotypes, and a workflow algorithm. AmpliChip CYP450 and some TaqMan single nucleotide variant (SNV) and copy number variant (CNV) data in the Genome-based therapeutic drugs for depression (GENDEP) study were used to select 95 samples (out of 853) to represent as broad a range of CYP2D6 and CYP2C19 genotypes as possible. These 95 included a larger range of CYP2D6 hybrid configurations than have previously been reported using inter-technology data. Genotyping techniques employed were: further TaqMan CNV and SNV assays, xTAGv3 Luminex CYP2D6 and CYP2C19, PharmacoScan, the Ion AmpliSeq Pharmacogenomics Panel, and, for samples with CYP2D6 hybrid configurations, long-range polymerase chain reactions (L-PCRs) with Sanger sequencing and Luminex. Agena MassARRAY was also used for CYP2C19. This study has led to the development of a broader range of TaqMan SNV assays, haplotype phasing methodology with TaqMan adaptable for other technologies, a multiplex genotyping method for efficient identification of some hybrid haplotypes, a customizable automated translation of SNV and CNV data into haplotypes, and a clinical workflow algorithm. |
format | Online Article Text |
id | pubmed-8608805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-86088052021-12-03 Methodology for clinical genotyping of CYP2D6 and CYP2C19 Carvalho Henriques, Beatriz Buchner, Avery Hu, Xiuying Wang, Yabing Yavorskyy, Vasyl Wallace, Keanna Dong, Rachael Martens, Kristina Carr, Michael S. Behroozi Asl, Bahareh Hague, Joshua Sivapalan, Sudhakar Maier, Wolfgang Dernovsek, Mojca Z. Henigsberg, Neven Hauser, Joanna Souery, Daniel Cattaneo, Annamaria Mors, Ole Rietschel, Marcella Pfeffer, Gerald Hume, Stacey Aitchison, Katherine J. Transl Psychiatry Article Many antidepressants, atomoxetine, and several antipsychotics are metabolized by the cytochrome P450 enzymes CYP2D6 and CYP2C19, and guidelines for prescribers based on genetic variants exist. Although some laboratories offer such testing, there is no consensus regarding validated methodology for clinical genotyping of CYP2D6 and CYP2C19. The aim of this paper was to cross-validate multiple technologies for genotyping CYP2D6 and CYP2C19 against each other, and to contribute to feasibility for clinical implementation by providing an enhanced range of assay options, customizable automated translation of data into haplotypes, and a workflow algorithm. AmpliChip CYP450 and some TaqMan single nucleotide variant (SNV) and copy number variant (CNV) data in the Genome-based therapeutic drugs for depression (GENDEP) study were used to select 95 samples (out of 853) to represent as broad a range of CYP2D6 and CYP2C19 genotypes as possible. These 95 included a larger range of CYP2D6 hybrid configurations than have previously been reported using inter-technology data. Genotyping techniques employed were: further TaqMan CNV and SNV assays, xTAGv3 Luminex CYP2D6 and CYP2C19, PharmacoScan, the Ion AmpliSeq Pharmacogenomics Panel, and, for samples with CYP2D6 hybrid configurations, long-range polymerase chain reactions (L-PCRs) with Sanger sequencing and Luminex. Agena MassARRAY was also used for CYP2C19. This study has led to the development of a broader range of TaqMan SNV assays, haplotype phasing methodology with TaqMan adaptable for other technologies, a multiplex genotyping method for efficient identification of some hybrid haplotypes, a customizable automated translation of SNV and CNV data into haplotypes, and a clinical workflow algorithm. Nature Publishing Group UK 2021-11-22 /pmc/articles/PMC8608805/ /pubmed/34811360 http://dx.doi.org/10.1038/s41398-021-01717-9 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Carvalho Henriques, Beatriz Buchner, Avery Hu, Xiuying Wang, Yabing Yavorskyy, Vasyl Wallace, Keanna Dong, Rachael Martens, Kristina Carr, Michael S. Behroozi Asl, Bahareh Hague, Joshua Sivapalan, Sudhakar Maier, Wolfgang Dernovsek, Mojca Z. Henigsberg, Neven Hauser, Joanna Souery, Daniel Cattaneo, Annamaria Mors, Ole Rietschel, Marcella Pfeffer, Gerald Hume, Stacey Aitchison, Katherine J. Methodology for clinical genotyping of CYP2D6 and CYP2C19 |
title | Methodology for clinical genotyping of CYP2D6 and CYP2C19 |
title_full | Methodology for clinical genotyping of CYP2D6 and CYP2C19 |
title_fullStr | Methodology for clinical genotyping of CYP2D6 and CYP2C19 |
title_full_unstemmed | Methodology for clinical genotyping of CYP2D6 and CYP2C19 |
title_short | Methodology for clinical genotyping of CYP2D6 and CYP2C19 |
title_sort | methodology for clinical genotyping of cyp2d6 and cyp2c19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8608805/ https://www.ncbi.nlm.nih.gov/pubmed/34811360 http://dx.doi.org/10.1038/s41398-021-01717-9 |
work_keys_str_mv | AT carvalhohenriquesbeatriz methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT buchneravery methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT huxiuying methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT wangyabing methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT yavorskyyvasyl methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT wallacekeanna methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT dongrachael methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT martenskristina methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT carrmichaels methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT behrooziaslbahareh methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT haguejoshua methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT sivapalansudhakar methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT maierwolfgang methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT dernovsekmojcaz methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT henigsbergneven methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT hauserjoanna methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT souerydaniel methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT cattaneoannamaria methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT morsole methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT rietschelmarcella methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT pfeffergerald methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT humestacey methodologyforclinicalgenotypingofcyp2d6andcyp2c19 AT aitchisonkatherinej methodologyforclinicalgenotypingofcyp2d6andcyp2c19 |